Trial Profile
A Phase II study evaluating short course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2010
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Cancer metastases; Rectal cancer
- Focus Therapeutic Use
- 02 Nov 2009 New trial record